16 results
PRE 14A
ANEB
Anebulo Pharmaceuticals Inc
19 Oct 23
Preliminary proxy
5:18pm
stage biotechnology company developing therapeutics targeting chronic and age-related diseases, from November 2014 to March 2022. From December 2012
DEFR14A
ANEB
Anebulo Pharmaceuticals Inc
25 Oct 22
Revised proxy
5:27pm
for the treatment of chronic and age-related diseases, from March 2016 to December 2018. Mr. Allen was a consultant to Solstice Biologics, a biotechnology … , Inc., a publicly traded clinical stage biotechnology company developing therapeutics targeting chronic and age-related diseases, from November 2014
8-K
bvxly0n
24 May 22
Anebulo Pharmaceuticals Appoints Kenneth Cundy, Ph.D., as Chief Scientific Officer
4:05pm
8-K
EX-99.1
wrqdh
24 May 22
Anebulo Pharmaceuticals Appoints Kenneth Cundy, Ph.D., as Chief Scientific Officer
4:05pm
8-K
1io9m6b6n43fcjhzu9
5 Jan 22
Anebulo Pharmaceuticals Names Biotechnology Industry Executive Simon Allen
10:00am
10-K
rh2qh42pquu0
22 Sep 21
Annual report
4:45pm
424B4
bk3txieddzy7 wks2
10 May 21
Prospectus supplement with pricing info
4:52pm
S-1/A
43y adpz1
26 Apr 21
IPO registration (amended)
4:38pm
S-1
etbvd7twhc7tjdwq7r
1 Apr 21
IPO registration
5:19pm
DRS/A
htwrthz8dqf9qks7r
12 Mar 21
Draft registration statement (amended)
12:00am
DRS
5rhysyqt qlexad5i
29 Jan 21
Draft registration statement
12:00am
- Prev
- 1
- Next